Repurposing FDA-approved drugs for treatment of amyotrophic lateral sclerosis using machine learning.
Journal:
Amyotrophic lateral sclerosis & frontotemporal degeneration
Published Date:
Jul 31, 2025
Abstract
INTRODUCTION: Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by loss of motor neurons. Current medications are largely ineffective, associated with side effects, and hindered by a lack of agreement over treatment pathways. The time-intensive process and high costs further limit the development of therapeutics. Therefore, this research aimed to identify FDA-approved drugs that inhibit three proteins (Casein kinase 1, Protein tyrosine kinase 2, Ephrin type-A receptor 4) associated with ALS.
Authors
Keywords
No keywords available for this article.